This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06299098 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 2 |
| Sponsor | Regeneron Pharmaceuticals |
| Enrollment | 1,005 participants |
| Design | Interventional, Randomized, Sequential, Masking: Quadruple |
| Conditions | Obesity |
| Interventions | Trevogrumab-Part A; Trevogrumab-Part B and Part C; Garetosmab; Semaglutide; Matching Placebo-Part A; Matching Placebo-Trevogrumab; Matching Placebo-Garetosmab |
| Start | Mar 13, 2024 |
| Primary completion | Jun 16, 2026 |
| Study completion | Oct 21, 2026 |
| Results posted | Not yet |
| Registry last updated | Sep 1, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested.
Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity.
The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy.
Parts A, B, and C of the study are looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Incidence of treatment-emergent adverse events (TEAEs) | Baseline to week 7 |
| Severity of TEAEs | Baseline to week 7 |
| Percent change in total fat mass | Baseline to week 26 |
| Percent change in total lean mass | Baseline to week 26 |
| Percent change in body weight | Baseline to week 26 |
| Percent change in total fat mass | Baseline to week 52 |
| Percent change in total lean mass | Baseline to week 52 |
| Percent change in body weight | Baseline to week 52 |
21 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 30, 2026. See the trial changes feed for what has changed recently.
More trials of Trevogrumab
Research area: Related non-peptide compounds. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
